Phase 3 Readout
BCAX: Phase 3 Topline: A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in C
July 1, 2029 · ficerafusp. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- July 1, 2029
- Company
- Bicara Therapeutics Inc. (BCAX)
- Drug
- ficerafusp
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in C
- Drug
- ficerafusp
- Indication
- Metastatic Head and Neck Squamous Cell Carcinoma; Recurrent Head and Neck Squamous Cell Carcinoma